JPMorgan Chase & Co. Reiterates Overweight Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reaffirmed by investment analysts at JPMorgan Chase & Co. in a research note issued to investors on Monday, MarketBeat reports.

Other analysts have also issued research reports about the company. Jefferies Financial Group increased their price objective on AstraZeneca from GBX 71 ($0.94) to GBX 74 ($0.98) and gave the company a “hold” rating in a report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £110 ($145.31) price target on shares of AstraZeneca in a research note on Tuesday, September 3rd. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research note on Thursday, July 25th. Citigroup reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, May 28th. Finally, Berenberg Bank reiterated a “buy” rating and issued a £150 ($198.15) target price on shares of AstraZeneca in a research note on Monday, September 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of £105.53 ($139.41).

AstraZeneca Stock Down 0.4 %

Shares of AstraZeneca stock opened at £119.68 ($158.10) on Monday. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The company has a market cap of £185.50 billion, a P/E ratio of 3,835.90, a PEG ratio of 0.93 and a beta of 0.17. The firm’s 50 day moving average price is £125.80 and its 200-day moving average price is £119.19. AstraZeneca has a 52-week low of GBX 9,461 ($124.98) and a 52-week high of £133.88 ($176.86).

Insider Activity at AstraZeneca

In related news, insider Michel Demare bought 2,000 shares of the stock in a transaction dated Friday, September 13th. The shares were purchased at an average price of GBX 118 ($1.56) per share, for a total transaction of £2,360 ($3,117.57). 0.04% of the stock is currently owned by insiders.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.